[Study on in vitro and in vivo antibacterial activity of pheromonicin-SA].
OBJECTIVE
To evaluate the bactericidal activity of pheromonicin-SA (Ph-SA) via routine in vitro/in vivo measurement.


METHODS
Minimal inhibitory concentration (MIC50 and MIC90) of Ph-SA were evaluated via in vitro double-dilution assay with 69 strains pathogenic bacteria and via intraperitoneal infected mice with intravenous Ph-SA treatment.


RESULTS
In vitro data showed that bactericidal activity of Ph-SA was approximately 12 times greater, on a molar basis, than that of vancomycin. In vivo data showed that bactericidal activity of Ph-SA was approximately 59 times greater than that of vancomycin.


CONCLUSIONS
The results suggest that Ph-SA may be of potential value as antibiotic against methicillin-resistant Staphylococcus aureus (MRSA).
Huang
Yan
Y
Key Laboratory of Transplant Engineering and Immunology, the Ministry of Health, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhang
Jie
J
Dai
Ping
P
Qiu
Xiao-qing
XQ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics*; D004352:Drug Resistance, Microbial; D005260:Female; D008297:Male; D016106:Methicillin Resistance; D051379:Mice; D008826:Microbial Sensitivity Tests; D010452:Peptide Biosynthesis; D010455:Peptides / Q000235:genetics*; D010456:Peptides, Cyclic; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
C414532:AgrD protein, Staphylococcus; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D010455:Peptides; D010456:Peptides, Cyclic; D011993:Recombinant Fusion Proteins; D014640:Vancomycin